GSK (LON:GSK) Share Price Breaks Below 50-Day Moving Average - Should You Sell?

Shares of GSK plc (LON:GSK - Get Free Report) passed below its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of GBX 1,849.02 and traded as low as GBX 1,783.50. GSK shares last traded at GBX 1,822.50, with a volume of 52,664,949 shares trading hands.

Key Headlines Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Quarterly results exceeded expectations. GSK reported approximately £8.9 billion in third-quarter sales, while core operating profit and core EPS came in modestly ahead of analyst estimates. GSK tops third-quarter estimates as new medicines drive growth, keeps outlook
• Positive Sentiment: Specialty medicines and newer products supported growth. The performance of new medicines helped offset pressure in vaccines, reinforcing GSK’s strategy of emphasizing specialty drugs and higher-growth products. GSK delivers Q3 earnings beat, reaffirms 2026 outlook
• Positive Sentiment: GSK plans to expand its oncology pipeline. The company is expected to nearly double the number of cancer medicines in clinical trials next year, a potential long-term catalyst for its specialty-medicines portfolio. GSK to nearly double cancer drugs in trials
• Neutral Sentiment: Full-year guidance was maintained. GSK reaffirmed its outlook for 3%–5% turnover growth and 7%–9% growth in core operating profit and core EPS. While this provides stability, investors appeared disappointed that management did not raise its forecast after the earnings beat. GSK keeps guidance as specialty drugs power sales
• Negative Sentiment: Vaccine sales weakened. Total vaccine revenue fell 2%, including a 5% decline for Shingrix and a 24% drop for Arexvy. The deterioration overshadowed growth in specialty medicines and raised concerns about the near-term outlook for key vaccine brands. GSK slides as weak vaccine sales overshadow quarterly beat
• Negative Sentiment: Restructuring charges reduced reported profitability. A £328 million charge connected with GSK’s Accelerate Growth program contributed to a 16% decline in reported operating profit and a 21% fall in total EPS, masking the underlying operating beat. GSK Q3 2026: Revenue blowout masked by restructuring charges

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on GSK shares. Royal Bank Of Canada reiterated a "sector perform" rating and issued a GBX 1,975 target price on shares of GSK in a report on Tuesday, September 8th. Jefferies Financial Group restated a "buy" rating and set a GBX 2,500 price target on shares of GSK in a report on Tuesday, October 20th. Berenberg Bank raised their price target on GSK from GBX 2,000 to GBX 2,200 and gave the stock a "hold" rating in a research report on Tuesday, September 15th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a GBX 2,000 price objective on shares of GSK in a research note on Tuesday, September 29th. Two analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of GBX 2,064.38.

GSK Stock Down 1.3%

The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. The business has a 50-day moving average price of GBX 1,849.02 and a 200-day moving average price of GBX 1,949.41. The firm has a market cap of £72.43 billion, a P/E ratio of 15.34, a P/E/G ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK - Get Free Report) last announced its quarterly earnings results on Wednesday, October 28th. The company reported GBX 54.60 earnings per share (EPS) for the quarter. The business had revenue of GBX 888.70 billion for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. On average, equities analysts forecast that GSK plc will post 175.98 EPS for the current fiscal year.

Insider Buying and Selling at GSK

In related news, insider Anne Beal acquired 637 shares of the company's stock in a transaction dated Friday, September 18th. The shares were purchased at an average cost of GBX 4,985 per share, with a total value of £31,754.45. Also, insider Jonathan Symonds bought 1,500 shares of the business's stock in a transaction that occurred on Friday, September 18th. The stock was purchased at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Insiders have bought 2,151 shares of company stock valued at $6,021,921 over the last quarter. Insiders own 0.20% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.